Chronic Myeloid Leukemia: 5 Things to Know Chronic Myeloid Leukemia: 5 Things to Know
In the wake of the tyrosine kinase inhibitor revolution, where is the treatment of CML headed?Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 17, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology Article Source Type: news
' Possibility of Cure' for Some Patients With CLL'Possibility of Cure' for Some Patients With CLL
Ibrutinib is rapidly changing the treatment landscape in chronic lymphocytic leukemia (CLL), and experts are now talking about the possibility of a cure for some patients.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 10, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Ibrutinib Combo in Chronic Lymphocytic Leukemia is Superior, but Costly
While ibrutinib plus rituximab may improve progression-free survival in chronic lymphocytic leukemia, it is a costly option for some patients. (Source: CancerNetwork)
Source: CancerNetwork - September 3, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news
Measurable Residual Disease Negativity at a High in Leukemia Trial
The CLARITY trial looked at measurable residual disease negativity in 54 patients with relapsed or refractory chronic lymphocytic leukemia who received ibrutinib in combination with venetoclax. (Source: CancerNetwork)
Source: CancerNetwork - August 20, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news
Promising Blood Test Could Help to Predict Breast Cancer Recurrence
Doctors have gotten much better at detecting and treating breast cancer early. Drug and chemotherapy regimens to control tumors have gotten so effective, in fact, that in some cases, surgery is no longer necessary. In up to 30% of cases of early-stage breast cancer treated before surgery, doctors can’t find evidence of cancer cells in postoperative biopsies. The problem, however, is that there is currently no reliable way to tell which cancers have been pushed into remission and which ones have not.
That’s where an easy identifier, like a blood test, could transform the way early stage breast cancer is treated....
Source: TIME: Health - August 8, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized blood tests Breast Cancer Source Type: news
Drug Duo May Be a Weapon Against a Common Leukemia
The phase 3 trial of more than 500 U.S. patients with chronic lymphocytic leukemia (CLL) found that a combination of rituximab and ibrutinib extended patient survival. (Source: WebMD Health)
Source: WebMD Health - August 1, 2019 Category: Consumer Health News Source Type: news
Ibrutinib-Rituximab Beats Chemoimmunotherapy for CLL
THURSDAY, Aug. 1, 2019 -- For patients with previously untreated chronic lymphocytic leukemia (CLL), ibrutinib-rituximab is more efficacious than chemoimmunotherapy, according to a study published in the Aug. 1 issue of the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 1, 2019 Category: Pharmaceuticals Source Type: news
Drug Duo May Be an Advance Against a Common Leukemia
WEDNESDAY, July 31, 2019 -- A two-drug combo helps patients with a common form of leukemia survive longer than the current standard of care, a new clinical trial finds.
The phase 3 trial of more than 500 U.S. patients with chronic lymphocytic... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 31, 2019 Category: General Medicine Source Type: news
Trump Signs 9/11 Victims Fund Extension
President Donald Trump on Monday signed legislation that will extend the September 11th Victim Compensation Fund until 2092.
During the signing ceremony at the White House, Trump was surrounding by first responders, survivors and family members of several who died in the 2001 terrorist attack on the United States.
The U.S. House of Representatives and the U.S Senate voted overwhelmingly last week to approve the legislation that will provide a lifetime of assistance for victims and their families.
The extension will allow the fund, first established in 2001, to pay for past and future medical claims of those effected by the...
Source: Asbestos and Mesothelioma News - July 29, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news
Senate Passes 9/11 Victim Compensation Fund Extension
The U.S. Senate followed the House of Representatives on Tuesday and passed legislation that will extend the September 11 Victim Compensation Fund until 2092.
The legislation will fund all current and future medical claims of those effected by the 9/11 terrorist attacks on the World Trade Center in New York City, the Pentagon in Washington, and United Flight 93, which crashed in Shanksville, Pennsylvania.
The extension of funding will benefit victims who may develop mesothelioma linked to the more than 400 tons of asbestos that covered the 16-acre disaster zone after the twin towers fell.
According to World Trade Center R...
Source: Asbestos and Mesothelioma News - July 23, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news
9/11 Victims Fund Passes Senate
The Senate gallery erupted in applause from politicians and first responders on Tuesday after a 97-2 vote to extend the September 11 Victim Compensation Fund until 2092.
The reauthorization will fund all current and future medical claims of those effected by the 9/11 terrorist attacks on the World Trade Center in New York City, the Pentagon in Washington, and United Flight 93, which crashed in Shanksville, Pennsylvania. The extension will allow victims and their families to file claims through 2090, but they will be paid out through 2092.
The extension of funding will benefit victims who may develop mesothelioma linked to ...
Source: Asbestos and Mesothelioma News - July 23, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news
Chronic Leukemia | Medscape Chronic Leukemia | Medscape
Chronic leukemias -- chronic myeloid leukemia and chronic lymphocytic leukemia -- occur mostly in adults and are extremely rare in children and young persons. Chronic lymphocytic leukemia has the highest familial incidence of the leukemias. (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 5, 2019 Category: Consumer Health News Tags: Resource Center Source Type: news
Value of Second-Generation TKIs Must Be Considered for CML Patients
Researchers looked at second-generation tyrosine kinase inhibitors at their current prices to test treatment value for patients with chronic myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - June 24, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news
SIRT1 plays key role in chronic myeloid leukemia to aid persistence of leukemic stem cells
(University of Alabama at Birmingham) Patients with chronic myeloid leukemia are treated with tyrosine kinase inhibitors. While these effective drugs lead to deep remission and prolonged survival, primitive leukemia stem cells resist elimination during the remission and persist as a major barrier to cure. In a study published in the Journal of Clinical Investigation, researchers show how the stress-responsive protein SIRT1 plays important roles in maintaining the regenerative potential of CML leukemic stem cells and promoting leukemia development in CML. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 10, 2019 Category: Biology Source Type: news
Diamonds Are Forever, but TKIs in CML Don't Have to Be Diamonds Are Forever, but TKIs in CML Don't Have to Be
Patients with chronic myeloid leukemia who undergo lifelong therapy with tyrosine kinase inhibitors have excellent outcomes. But treatment may not have to be forever.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 6, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
